<DOC>
	<DOCNO>NCT00795132</DOCNO>
	<brief_summary>This phase II trial reduce intensity conditioning Bu/Flu/ATG pediatric patient hematologic malignancy high risk transplant relate mortality standard transplantation . Patients qualify base organ system dysfunction , active stable infection , history previous transplant late stage disease . We plan enroll 45 patient Pediatric Blood Marrow Transplant Consortium ( PBMTC ) anticipate outcome trial pave way phase II III disease specific protocols address efficacy approach compare standard transplant approach good risk patient .</brief_summary>
	<brief_title>Hematopoietic Cell Transplantation Pediatric Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Summary/Proposal : Reduced Intensity Hematopoietic Cell Transplantation High-Risk Relapsed Pediatric Hematologic Malignancies Patients Ineligible Standard Transplantation We propose phase II trial reduce intensity conditioning Bu/Flu/ATG pediatric patient hematologic malignancy high risk transplant relate mortality standard transplantation . Patients qualify base organ system dysfunction , active stable infection , history previous transplant , late stage disease . We plan enroll 45 patient Pediatric Blood Marrow transplant Consortium ( PBMTC ) anticipate outcome trial pave way phase II III disease specific protocols address efficacy approach compare standard transplant approach good risk patient . Hypothesis High risk pediatric hematologic malignancy patient ineligible standard myeloablative HCT undergoing reduce intensity conditioning ( RIC ) HCT achieve sustain engraftment rate &gt; 90 % 100day TRM &lt; 30 % use either bone marrow PBSC relate unrelated donor . High risk pediatric patient undergo RIC-HCT use relate unrelated cord blood achieve sustain engraftment rate &gt; 80 % 100d TRM &lt; 30 % . Rationale Reduced Intensity Approaches High Risk Patients There number patient-specific risk factor associate increase transplant relate mortality . They broadly place three category : pretransplant organ system dysfunction , active infection time transplant , degree pretransplant therapy ( previous transplant , third subsequent remission , etc. ) . The primary objective study determine likelihood achieve sustain donor engraftment use reduce intensity conditioning ( fludarabine/busulfan/ATG ) follow hematopoietic cell transplantation ( HCT ) either cord blood , bone marrow peripheral blood stem cell ( PBMTC ) pediatric patient hematopoietic malignancy high risk transplant relate mortality ( TRM ) myeloablative HCT . Patients qualify base organ system dysfunction , active stable infection , history previous transplant late stage disease . We plan enroll 45 patient Pediatric Blood Marrow Transplant Consortium ( PBMTC ) anticipate outcome trial pave way phase II III disease specific protocols address efficacy approach compare standard transplant approach good risk patient . Study procedures Patients receive condition regimen consist fludarabine , busulfan , ATG receive stem cell transplant . Patients receive immunosuppression consist cyclosporine mycophenolate mofetil . Patients persistent progressive disease may receive donor lymphocyte infusion protocol .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . Patients must age 21 young must hematologic malignancy treatable allogeneic hematopoietic transplantation ( acute chronic leukemia , myelodysplasia lymphoma , see protocol detail ) . Patients qualify approach four way : 1 ) presence organ system dysfunction severe systemic infection significantly increase transplant relate mortality standard myeloablative transplant regimen , 2 ) history previous myeloablative allogeneic autologous transplantation , 3 ) currently third high CR receive unrelated stem cell transplant , 4 ) combination toxicity lead investigator feel child high risk ( &gt; 50 % ) TRM . Patients eligible inclusion base consideration number 4 enrol unless discuss study chair . 2 . Organ system dysfunction : least one follow organ system dysfunction criterion plus minimum organ function list exclusion criterion qualify patient treatment protocol 1 . Pulmonary : DLCO , FEV1 TLC/FVC &lt; 60 % predict . Patients young PFTs suspect pulmonary toxicity assess consult pulmonologist . If pulmonologist judge child moderatesevere pulmonary disease qualify inclusion . 2 . Renal : creatinine clearance &lt; 60ml/m/1.73m2 3 . Hepatic : transaminase &gt; 4x normal total bilirubin &gt; 2.0 4 . Cardiac : patient suspect cardiac toxicity undergo cardiac echo . If shortening fraction ( SF ) &lt; 25 % measurement ejection fraction must obtain . Patients qualify reduce intensity therapy SF &lt; 25 % EF &lt; 50 % . 3 . Infections : Patients responsive unresolved invasive infection . These infection may fungal , bacterial opportunistic infection . Viral infection meet eligibility criterion . 4 . Other patient group high risk transplant relate mortality : Patients history prior allogeneic autologous transplantation patient CR3 great receive unrelated stem cell transplant also eligible protocol . If investigator feel patient combination risk factor could increase risk transplant relate mortality &gt; 50 % standard transplantation may eligible inclusion , patient must review protocol chairman prior enrollment . 1 . Patients must CR ( &lt; 5 % blast BM morphology , active CNS disease , see protocol ) follow exception : 1 . AML may proceed M2 marrow status ( &lt; 20 % blast ) . 2 . Lymphoma : residual disease must responsive nonbulky ( &lt; 5cm large diameter ) . 3 . Myelodysplasia : Patients RA , RAEB eligible , RAEBIT patient eligible treat &lt; 5 % blast ( RA ) chemotherapy . 4 . CMLBP must treat CR/CP2 eligible . 2 . Females pregnant 3 . Patients HIV positive progressive infection 4 . Organ dysfunction : patient ineligible following level severe organ system dysfunction : 1 . Cardiac : Ejection fraction &lt; 30 % 2 . Pulmonary : Receiving continuous supplementary oxygen follow : DLCO &lt; 30 % , FVC/TLC &lt; 30 % FEV1 &lt; 30 % 3 . Hepatic : patient exclude hepatic synthetic dysfunction evidence follow : prolongation prothrombin time INR &gt; 2.0 , total serum bilirubin &gt; 3 , transaminase &gt; 10x normal . 4 . Renal : patient creatinine clearance &lt; 30ml/m/1.73m2 require dialysis eligible Donor Eligibility Criteria : 1 . Related unrelated donor 6/6 HLA match HLAA , B , DRB1 locus . 5/6 match acceptable mismatch class I alleles ( A B ) , DRB1 mismatch allow . Intermediate resolution type class I high resolution type class II alleles require . ( HLAC HLADQ match encourage , require ideal donor match 10/10 allele . ) 2 . Unrelated cord blood may use match HLAA , B DRB1 either 4/6 , 5/6 , 6/6 antigen . The minimum mononuclear cell dose require eligibility 3 x 107 mononuclear cells/kg recipient body weight ( base frozen cell dose ) . It strongly suggest back unit umbilical cord blood reserve , though request , case rejection . Donors must pass require institutional NMDP health infectious disease screening .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Hematopoietic Cell Transplantation</keyword>
</DOC>